According to the official annual financial report released by the company, Mriya ended 2013 with total sales revenue growth of 43.3% at USD 498.7 million compared to the result of 2012. Proceeds from changes in biological assets declined by -23.8% to USD 163.9 million. Costs of sales were reported at USD 430.8 million, which is 35.4% higher compared to 2012 level. Operating expense grew by 85.5% to USD 68.9 million in 2013, while financial expenses have increased by 127.5% to USD 72.2 million compared to 2012 levels. Company’s net income have declined by -49.4% to USD 88.4 million in 2013.

Company’s cash flow from operating expenses have declined by -37.8% to USD 104.2 million, cash flows from investing activities have decreased by 55.6% to USD -398.7 million and cash flows from financing activities have risen by 545.2% to USD 300.2 million, reflecting company’s strategy of attracting external investment funds.

UkrAgroConsult has completed review and recommendations study on investing in Ukrainian Agrarian Sector. You can follow this link to find out more about the study “How to profit from Ukraine’s agricultural sector?”. In case you are interested in state of agrarian sector within CIS region, please follow the link below to read UkrAgroConsult monthly report “Agrarian Business in CIS region” for January 2014 (featuring Ukraine). First issue is free of charge. You can subscribe to the report to receive it on a monthly basis.

UkrAgroConsult